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Imperial College London, London, UK
Bioactive glasses were discovered in 1969 and provided for the first time an alternative 
to nearly inert implant materials. Bioglass formed a rapid, strong, and stable bond with 
host tissues. This article examines the frontiers of research crossed to achieve clinical 
use of bioactive glasses and glass–ceramics. In the 1980s, it was discovered that 
bioactive glasses could be used in particulate form to stimulate osteogenesis, which 
thereby led to the concept of regeneration of tissues. Later, it was discovered that the 
dissolution ions from the glasses behaved like growth factors, providing signals to the 
cells. This article summarizes the frontiers of knowledge crossed during four eras of 
development of bioactive glasses that have led from concept of bioactivity to widespread 
clinical and commercial use, with emphasis on the first composition, 45S5 Bioglass®. 
The four eras are (a) discovery, (b) clinical application, (c) tissue regeneration, and (d) 
innovation. Questions still to be answered for the fourth era are included to stimulate 
innovation in the field and exploration of new frontiers that can be the basis for a general 
theory of bioactive stimulation of regeneration of tissues and application to numerous 
clinical needs.
Keywords: Bioglass, bioactive glass, inorganic/organic hybrids, sol–gel, scaffold, regenerative medicine, tissue 
engineering, synthetic bone grafts
iNTRODUCTiON
It is an honor to present this opening paper in this special journal issue devoted to frontiers of inorganic 
biomaterials. Our contribution focuses on the frontiers and unmet challenges of bioactive glasses. 
It is now nearly 50 years since the discovery of bioactive glasses bonding to living bone (Beckham 
et al., 1971; Hench et al., 1971; Hench and Paschall, 1973; Wilson et al., 1981). Many advances have 
been made in understanding mechanisms of bonding of this special compositional range of glasses 
to both bone and soft connective tissues. Numerous published reviews and books have documented 
these advances (Hench, 1991, 1998, 2015; Hench and Polak, 2002; Hench et  al., 2004; Rahaman 
et al., 2011; Jones, 2013). In the last decade, the primary clinical applications of bioactive glasses 
have involved turning on the body to repair its own bone, a process called osteostimulation, a term 
approved by the United States Food and Drug Administration (FDA). Osteostimulation refers to the 
activation of progenitor cells in the body, by a material or its dissolution products, producing more 
bone. The claim is based on in vivo data (Oonishi et al., 2000) that showed that Bioglass stimulates 
more rapid bone repair than other bioactive ceramics and the in vitro studies that revealed why this 
occurred, which was due to the dissolution products stimulating seven families of genes in primary 
human osteoblasts (Xynos et al., 2000a,b, 2001).
FiGURe 1 | Three realms of human knowledge.
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A recently published review summarizes the questions 
answered in four eras of development of bioactive glasses from 
the discovery in 1969 to the present, 2015 (Hench, 2015). The eras 
of development of bioactive glasses are
(A) Era of Discovery (1969–1979);
(B) Era of Clinical Application (1980–1995, C);
(C) Era of Tissue Regeneration (1995–2005);
(D) Era of Innovation (2005–2025).
Several important unanswered questions for the fourth era 
were suggested in the review (Hench, 2015). Each of these unan-
swered questions is at the frontier of understanding and control-
ling the interaction of bioactive glasses in the living body. The 
objective of this introductory paper is to discuss these questions 
further, suggest potential research directions that can answer 
them to move the frontiers of the field forward to achieve even 
more clinical applications for an aging population.
wHAT ARe FRONTieRS?
First, it is important to discuss the concept of frontiers of 
knowledge in general and the frontiers of biomedical materials 
specifically. We can divide human knowledge into three overlap-
ping and intersecting realms of knowledge: Nature, Self, and 
Social (Figure 1).
The first field of knowledge, called Nature, evolved over mil-
lennia as humans strived to understand the natural forces that 
influenced their lives. The subject was first titled natural history. 
At one time, it was suggested that natural historians such as Sir 
Francis Bacon possessed within his own mind most of what was 
known about the natural world at that time. Now in the twenty-
first century, it is impossible for any one individual to know or 
understand even a very small fraction of the knowledge of nature. 
The field has been divided into the major scientific disciplines of 
physics, chemistry, and biology then subsequently subdivided into 
an ever-increasing number of subdisciplines, such as astronomy, 
astrophysics, cosmology, quantum mechanics, solid-state physics, 
inorganic chemistry, organic chemistry, biochemistry, molecular 
biology, etc. Although enormous depth of understanding of these 
topics has been achieved, there are still many frontiers in the 
knowledge of nature. These frontiers are at the boundary between 
certainty and uncertainty. Those boundaries exist at the extremes 
of scale of distance and time limits of our universe. Distances 
of very small, sub nanometer size, and very large, light years in 
dimension, comprise the bounds of uncertainties. There are dis-
coveries every year that push back the age of the universe and the 
complexity and beauty of the subatomic particles that were created 
during the “Big Bang” beginning of the universe that comprise the 
atomic and molecular-based world that we live in today.
The knowledge of Self also emerged during the last few millen-
nia as a set of disciplines, such as anatomy, physiology, and psy-
chiatry. Intersections between the knowledge of Self and Nature 
have become ever more blurred in today’s scientific community 
with the application of many of the techniques used to explore the 
natural universe also applied to understanding the human body, 
the brain, and the mind. The frontiers of knowledge of Self are 
still largely unexplored and the origins of thought, memory, and 
emotions are active subfields of investigation. Advances in the 
understanding of Nature and Self have made it possible to control 
the life and the death of billions of humans.
The third sphere of knowledge, evolved over the last few hun-
dred years, can be considered Social knowledge. Subdisciplines, 
such as sociology, anthropology, economics, and political science, 
have been developed to attempt to explain the complex interrela-
tionships between individuals. Social knowledge includes small 
group interactions, such as couples, to large-scale interdepend-
ence of communities involving millions of individuals. Levels of 
uncertainty in the field of social knowledge are extremely high. 
This is because of the difficulty of predicting the behavior of large 
number of individuals interacting together. To become a science, 
it is necessary to achieve repeatable observation, verification, and 
quantification, followed by predictability. Such criteria are met in 
the natural sciences and the ever-increasing knowledge of Self.
However, there are high levels of unpredictability in the area 
of social knowledge. Thus, world conflicts continue to occur with 
enormous toll on human suffering and life without a means to pre-
dict or prevent such calamities. Unpredictable political changes, 
such as the breakup of the Soviet Republic were seldom, if at all, 
predicted by social scientists. Even breakups of interpersonal 
relationships of couples are, for the most part, unpredictable. 
Likewise, it is very difficult to predict the impact of a new medical 
therapy on the behavior of a large population. Self-delusion and 
susceptibility to persuasion can easily warp the attitude of large 
numbers of individuals and replace logical reasoning in decision 
making. As an example, many surgeons find it difficult to accept 
that a bioactive synthetic bone graft can be equal or superior to 
autogeneous bone (bone transplanted from another part of the 
patient), even though clinical studies have shown that to be the 
case for some applications, even though the autograft leads to 
donor site morbidity.
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Of particular concern in this introductory paper is a discus-
sion of the area where the three realms of knowledge overlap 
and intersect, as illustrated in Figure  1. Medicine, Dentistry, 
Biomedical Engineering, and Biomaterials lie at the intersec-
tion of the three realms of knowledge. This region could also 
be broadly named Healthcare. Here, the uncertainties of each 
realm of Nature, Self, and Social, are additive and perhaps even 
multiplicative. Thus, it becomes nearly impossible to predict the 
effects on long-term survivability (20–40 years) of a change in a 
biomaterial or device in a single individual. This is because the 
healthcare predictions, derived from overlapping regions of the 
three realms of knowledge, are based upon statistical results of 
the survivability of a large number of patients. The uniqueness 
of an individual is not reflected in statistical data, only within the 
distribution of results.
This fact is extremely important to recognize, as the field of 
repair and regeneration of the human body increases to deal 
with an aging population numbering in the hundreds of mil-
lions. It is important for the entire healthcare community, and 
the general public, to recognize that there are no such things as 
miracle materials or miracle cures. There is always the possibility 
of failure. Failure is not necessarily the fault of any individual, 
surgeon, company, or hospital. Failures of materials, devices, 
and biotechnology are a natural consequence of the large-scale 
complexity of the human body and its intricate interactions in a 
social environment where outside influences affect uncertainty 
of the quality of life of the individual as well as the length of life.
Let us discuss one example of an unmet challenge to illustrate 
the impact of the uncertainties of these overlapping regions of 
knowledge on inorganic biomaterials device development. During 
the last 40 years, numerous research efforts have been made to 
develop a long-term stable (not biodegradable) load-bearing 
replacements for diseased, damaged, or missing bone. The closest 
bioceramic to achieve this objective was the apatite–wollastonite 
(A/W) bioactive glass–ceramic, Cerabone, developed in Japan, 
at the University at Kyoto, by professors Yamamuro, Kokubo, 
Nakamura, and colleagues (Kokubo et al., 1990). Tens of thou-
sands of successful Cerabone implants were made and implanted 
for a variety of orthopedic applications in Japan, especially in 
spinal repair. Excellent clinical success was achieved for all of the 
devices. However, a very high stiffness (elastic modulus) led to 
concern about long-term stress shielding in high load-bearing 
applications. Stress shielding occurs when load is transmitted 
through the implant, and it is not transmitted to the surround-
ing bone. When bone is not loaded, it loses volume as the body 
removes it through osteoclast cell activity. A high production cost 
also limited commercial interest. The product was not introduced 
internationally and is no longer on the market. Thus, the goal of 
replacing load-bearing cortical bone is still an unmet challenge.
Our issues of concern are the uncertainties associated with 
the intersections of the three worlds of knowledge. The laws of 
nature make it possible to perform accurate mechanical testing 
of a new biomaterial, such as a potential load-bearing bioactive 
ceramic. Mechanical testing can be extended to a sufficiently large 
number of test devices to establish the distribution of results and 
strain rate dependencies of strength can lead to lifetime predic-
tion diagrams of the mechanical behavior under particular levels 
of load. The science behind the knowledge of Self now makes it 
possible to obtain quantitative computed tomography (CT) data 
(Midha et  al., 2013), and by use of rapid prototyping replicate 
precisely, the anatomical shape needed for a device made of a new 
load-bearing bioactive ceramic (Brie et  al., 2013). The science 
of ceramic, glass, and glass–ceramic processing is sufficiently 
advanced to make individual components by rapid prototyping or 
computer-guided machining at reasonable cost. Developments, 
such as 3-D printing, make it possible to manufacture anisotropic 
microstructures that mimic the structure of cortical bone as well 
as trabecular bone (Fu et al., 2011a,b).
Uncertainties, however, have great impact on the economics of 
the overlap between Nature, Self, and Society. Limitations on new 
medical product development come in several forms. Achieving 
governmental regulatory approval of a new device that must last 
for many years requires a highly rigorous set of simulation testing 
and large monetary investment. The keyword here is simulation. 
Simulated body solutions are a standard use in the bioceramics 
testing field and have been adopted as international and regula-
tory standards (Macon et  al., 2015). However, the non-cellular 
simulated body fluids do not lead to an ability to predict in long 
term the effect of a physiological body environment on a material 
or device that is exposed to a complex mixture of mechanical 
loads (Bohner and Lemaitre, 2009). It is well known that bone 
cells respond to mechanical cues and the architecture and the 
quality of bone that forms is dependent on those cues. Multiaxial 
fatigue data can be generated under simulated physiological con-
ditions, but such environments do not embrace the uncertainty of 
the effect of the living bone – bioactive ceramic contact area and 
its changes with time and physiology of the patient.
Especially important is the fact that there is no way to predict the 
effect of age and load distribution on the mechanical properties of 
the loaded bone bonded to the bioactive ceramic. Consequently, 
in order to have a sufficiently acceptable set of preclinical data, 
it is necessary to establish reasonably equivalent animal data for 
the regulatory authorities. Approval for clinical application of an 
innovative bioactive load-bearing bioceramic will require large 
animal data. This is where the overlap of Nature, Self, and Social 
is especially important because the cost of producing large animal 
data for a statistically significant number of implants is very high.
The costs escalate after successful animal data has been gener-
ated because most regulatory agencies will require clinical trials. 
The number is large because there is no predicate load-bearing 
cortical bone implant to establish equivalence under the FDA 
510K provisions. It is very difficult to predict the cost of clinical 
trials because the survivability for approval must surely be estab-
lished for a minimum of three, and more than likely 5 years. Thus, 
the cumulative cost of bringing a new product, such as a new 
bioactive ceramic material, into the market is in the millions of 
dollars. Although there are tens of thousands such devices poten-
tially needed annually, it is very hard to calculate the potential 
cost/profit or risk/reward ratios. These limitations and barriers 
to achieving frontiers of clinical use are independent of the 
successful development of the biomaterial that satisfies the ideal 
combination of properties needed for cortical bone; i.e., strength, 
toughness, fatigue resistance, bioactivity, and elastic modulus that 
do not shield the bone from stress following bonding to bone.
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The above example illustrates our opinion that emphasis on 
“improved” bioactive ceramics, where the primary function of 
the material is to replace the diseased, damaged, or missing tissue 
is unlikely to have many successes that are economically viable. 
These considerations lead to the conclusion that the most signifi-
cant long-term frontier is expansion of efforts in the field toward 
the frontiers of regenerative medicine. This era of innovation 
will be discussed briefly next. The critical unmet challenges and 
frontiers will be discussed later. However, let us first look at what 
can be considered a frontier in this field of inorganic biomaterials.
The word frontier implies exploring the unknown hoping to 
find within the unknown something new and useful. In directed 
research, such as biomaterials, new and important developments 
are driven by clinical need and limited by economics and long-
term survivability. Deciding which frontiers to explore is a difficult 
and demanding step for a research group or company. The history 
of the field has shown that there are indeed very few frontiers that 
have been crossed, although there have been thousands of efforts 
to achieve long-term improvement of biomaterials in general.
An example from the field of bioactive glasses and glass–
ceramics can be useful in establishing what is and what is not 
a frontier of research in the field. The very first material that 
was found to form a bond with bone was the original bioactive 
glass composition, 45S5 Bioglass (45 wt% SiO2, 24.5 wt% CaO, 
24.5 wt% Na2O, and 6 wt% P2O5) (Hench et al., 1971). Much of 
the time in the era of discovery was devoted to understanding 
the mechanisms of bonding and the nature of the bonds between 
the glass and bone and soft tissue (Hench and Polak, 2002). This 
can be considered a major frontier because up until the time of 
this discovery, it was assumed that all foreign materials would be 
isolated from the living tissue by a thin acellular fibrous capsule. 
The discovery showed that encapsulation was not a fundamental 
restriction of the response of the body to foreign material. When 
rapid reactions occur at the surface of a bioactive glass or glass–
ceramic, the biologically active hydroxyapatite (HA) layer quickly 
masks the material from immune cells. The cellular recognition 
mechanisms respond to it as if it were a layer of newly mineralizing 
bone: the cells attach and extracellular matrix (ECM) is produced, 
mineralization proceeds to completion and newly formed bone is 
strongly anchored to the surface of the material with an interfacial 
bond strength equal to or greater than the natural bone (Hench 
et al., 1971). Another frontier was discovery of the bonding of the 
most bioactive of the Bioglasses to soft connective tissues as well 
as bone through an equivalent mechanism of surface reactions to 
form a hydroxyl-carbonate apatite layer but with a thicker bond-
ing interface (Wilson and Noletti, 1990).
The compositional boundary between bonding to bone and 
non-bonding was found to be in the range of 60  wt% silica 
(Hench, 1998). Effects of additional oxide compositions on 
the details of the compositional boundaries have been looked 
at extensively in the decades since (Hoppe et  al., 2011). Some 
investigators proclaim that addition of other oxides to the bio-
active glass to enhance the bone bonding is searching the new 
frontier. This objective is open to question because the measure 
of frontier advances is delivery of clinical products. Small incre-
mental advances showing a few percent more bone growth in 
a 30-day period of time is questionable as frontier research, as 
the small increase will not warrant the investment required to 
get the new material to market. However, the realization that 
the dissolution ions caused osteostimulation was the crossing of 
an important frontier: cell stimulation by a synthetic material 
without organic growth factors. If additional therapeutic benefits 
of other cations can be proven, there is great potential to use 
bioactive glass as a reservoir for sustained delivery of active ions 
that can be specific to different medical conditions. An example 
is strontium oxide, where controlled release of strontium ions, 
from the glass, is thought to be beneficial for osteoporosis as it 
can slow osteoclast activity (Lao et al., 2008; Gentleman et al., 
2010; Autefage et al., 2015).
What is frontier research in bioactive materials? Returning 
back to the discussion of long-term survivability of load-bearing 
long bone implants, research done up to now has not delivered 
such a material. Consequently, the concept of tissue regeneration 
to enhance bone formation that is capable of long-term load-
bearing is now at the highest level of frontier investigations. This 
is because the concept of tissue regeneration is to use the material 
not to replace the diseased, damaged, or missing part of the body, 
but instead activates the body’s own repair mechanism so that 
the tissue that is grown is replicating both biochemically and 
biomechanically the original load-bearing tissue. This eliminates 
the problems of stress shielding and particularly the problem of 
remodeling of the material or interface when the load distribu-
tion changes or health deteriorates. Thus, an active frontier area 
includes developing an ideal bioactive scaffold for bone that is 
capable of providing short-term strength with high reliability that 
is transformed into load-bearing bone and then resorbed. This is 
one of the most significant levels of frontiers and the progress to 
achieve it is a highlight of the decade of innovation.
Designing hybrid biomaterials that are bioactive and have 
controlled rates of resorption and can be molecularly tuned to 
produce particular combinations of mechanical properties is a 
major goal of the era of innovation, as discussed in a recent review 
(Jones, 2013). Success in achieving an ideal scaffold for bone as 
a frontier would have a large impact on the field. It would open 
exploration to achieve an ideal scaffold for cartilage regeneration 
that could provide a long-term solution to the extensive revisions 
now required for replacement of total hip and knee prostheses due 
to the biomechanical limitations discussed above. The frontier of 
designing bioactivity to activate the genetic repair mechanisms 
for specific lineages of connective tissues is at the highest level 
of frontier research and will be emphasized in the list of unmet 
challenges to follow. Of course, to cross the frontiers, the new 
devices must be translated to clinical products.
eRA OF DiSCOveRY (1969–1979) 
FRONTieRS
The most significant frontier was the discovery in 1969 by 
Hench, Splinter, Allen, and Greenlee that certain compositions 
of Na2O–CaO–P2O5–SiO2 glasses formed a strong, adherent 
bond to bone (Hench et  al., 1971). These biomaterials have 
become known as “bioactive,” reacting in the physiological envi-
ronment to form a bond between an artificial material and living 
TABLe 1 | Composition and properties of bioactive glasses and  
glass–ceramics used clinically for medical and dental applications.
Composition 
(wt%)
45S5 Bioglass 
(NovaBone, Perioglas, 
NovaMin, Biogran)
S53P4 
(AbminDent1, 
BonAlive)
A–w glass–
ceramic 
(Cerabone)
Na2O 24.5 23 0
CaO 24.5 20 44.7
CaF2 0 0 0.5
MgO 0 0 4.6
P2O5 6 4 16.2
SiO2 45 53 34
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tissue. Studies showed stable and strong bonding between bone 
and soft tissues in a wide range of mammals: mice, rats, guinea 
pigs, rabbits, dogs, sheep, pigs, monkeys, and baboons. A stable 
bone-bonded implant in the anterior region of the mandible of 
a baboon after 4 years of functional use was reported, one of the 
longest in vivo studies of biomaterials in primates ever published 
(Stanley et al., 1981).
The second frontier was development of in vitro and in vivo 
tests that established the mechanisms and limits of bonding of 
bioactive glasses and glass–ceramics to bone. The in vitro tests 
showed that the 45S5 Bioglass composition (see Table 1) devel-
oped a HA layer in test solutions. This HA phase developed on the 
surface of the implants in vitro was equivalent to the interfacial 
HA crystals observed in  vivo by Dr. Greenlee’s transmission 
electron micrographs of the bonded interface. The HA crystals 
in vivo were bonded to layers of collagen fibrils produced at the 
interface by osteoblasts. The chemical bonding of the HA layer to 
collagen created the strongly bonded interface (Beckham et al., 
1971; Hench et al., 1971; Hench and Paschall, 1973).
During the era of discovery, a series of questions was addressed 
(Hench, 2015). Some of the key questions are summarized here. 
Question: What is the nature of the bioactive bond? Answer: 
hydroxycarbonate apatite (HCA) crystals bonded to collagen fib-
ers (Beckham et al., 1971; Hench et al., 1971; Hench and Paschall, 
1973). Question: What mechanisms are involved in HCA forma-
tion? Answer: five surface reactions at the glass surface occur 
(cation exchange, Si–OH group formation, on which amorphous 
calcium phosphate phase deposits, crystallizing to HCA, which 
binds to collagen). Question: How strong is the bond? Answer: 
stronger than the host bone (Piotrowski et al., 1975). Question: 
What compositions of glass can form the bond? 45S5 Bioglass 
is composed of SiO2–CaO–Na2O–P2O5 (Table 1). In this system, 
bonding to both bone and soft tissue is possible at 52 wt% SiO2 
(Wilson et al., 1981) and between 52 and 60% SiO2 bonding is 
only to bone (Hench, 1998).
Two important aspects of the frontiers were explored in 
the Era of Discovery. First, the methodology for investigating 
the reactive glass surface and bonded interfaces of bioactive 
implants with living tissues had to be developed. There was 
no precedent for such analyses. Examples are instrumental 
techniques such as infrared reflection spectroscopy, developed 
by Sanders and Hench (1973), and applied to bioactive glasses 
and cryogenic Auger electron spectroscopy (AES), developed 
by Ohuchi, Pantano, Ogino, and Hench (Clark et  al., 1976; 
Ogino and Hench, 1980; Ogino et al., 1980). At this stage, tests 
were conducted primarily on bulk samples or as bioactive coat-
ings on metal, e.g., Co–Cr alloys, or ceramic (e.g., alumina) 
implants. It was assumed that the eventual applications of 
bioactive bonding would be to replace a diseased or damaged 
bone. The second Era of Clinical Applications was based upon 
this knowledge.
eRA OF CLiNiCAL APPLiCATiON 
FRONTieRS (1980–1995)
An important frontier to cross was clinical translation. The dis-
covery by Wilson et al. (Wilson et al., 1981; Wilson and Noletti, 
1990) that Bioglass could bond to soft tissue paved the way for 
development of the first bioactive glass clinical applications that 
required both stable bone and soft tissue interfaces: the MEP 
(middle ear replacement prostheses) (Merwin et al., 1982) and 
ERMI, endosseous ridge maintenance implants (Stanley et  al., 
1997). These devices had the objective of replacing diseased, 
damaged, or missing body parts that require stable bonding to 
both soft tissues and bone. At the time, most other types of middle 
ear prostheses were lost by extrusion after a few years. In contrast, 
Bioglass middle ear devices formed a stable bond to both bone, 
such as the stapes footplate and the soft tissues of the tympanic 
membrane and thus remained stable for more than 10 years as 
reported in follow-up studies at both the University of Florida 
and Guy’s Hospital in London (Rust et al., 1996). Equivalent long 
term, >10  years, success of the Bioglass ERMIs were reported 
by Stanley et al. Alternative Class B bioactive implants made of 
synthetic HA were lost by extrusion or exfoliation from the jaw 
after only a few years post implantation. In contrast, 45S5 Bioglass 
implants maintained stable bonding in alveolar bone and a stable 
gingival interface for long term and maintained thickness of the 
bone without resorption generally experienced by denture wear-
ers (Wilson et al., 1993; Stanley et al., 1997).
A second frontier crossed by Wilson et al. (1981) was the col-
lation of results of sixteen in vitro and in vivo tests that established 
the safety of use of particulate forms of Bioglass in addition to the 
bulk implants (Wilson et al., 1981). These data provided the basis 
for ethical committee’s approval of the use of Bioglass in clinical 
trials at the University of Florida and Guy’s Hospital in London, 
as well as application for regulatory approval of commercial sales 
of these devices by the FDA and a CE mark from the EU. This led 
to the use of Bioglass in bone regeneration (Hench et al., 2004).
eRA OF TiSSUe ReGeNeRATiON 
FRONTieRS (1985–2005)
The discovery of osteoproduction (osteostimulation) and 
the concept of using Bioglass particulate for regeneration of 
bone was the key frontier crossed that led to the Era of Tissue 
Regeneration. Wilson et al. described the effect of various sizes 
of Bioglass particulate on regeneration of bone in periodontal 
defects created in a monkey model (Wilson and Low, 1992). The 
seminal finding was the stimulation of new bone throughout the 
defect. Bone growth was initiated at the surface of the bioactive 
FiGURe 2 | (A) Packaging of NovaBone (45S5 Bioglass) powder for orthopedic applications and (B) scanning electron micrograph of NovaBone particles. Modified 
with permission from Jones (2013).
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glass particles and rapidly formed connections between the 
particles regenerating a trabecular bone network that mimicked 
the original trabecular bone of the jaw prior to creating the defect. 
The study showed that there was an optimal rate of bone repair 
when a range of particle sizes of Bioglass was used. The results 
also showed that bone regeneration was sufficiently rapid that 
it prevented encapsulation of the site by epithelial tissues. The 
data provided the foundation for a clinical trial in patients at the 
University of Florida that led to FDA regulatory approval of the 
use of bioactive glass particulate for periodontal repair (Perioglas, 
NovaBone Products LLC, Alachua, FL, USA; Figure 2).
NovaBone was compared to autograft in posterior spinal 
fusion operations for treatment of adolescent idiopathic scoliosis 
(curvature of the spine) in 88 patients (Ilharreborde et al., 2008). 
NovaBone performed as well as autograft over 4 years but with 
fewer infections (2 versus 5%) and fewer mechanical failures (2 
versus 7.5%).
The first non-45S5 composition to reach the market was S53P4 
(Table  1), now known as BonAlive® (BonAlive Biomaterials, 
Turku, Finland), which received European approval for orthope-
dic use as bone graft substitute in 2006. It has higher silica content; 
so bioactivity is expected to be lower than 45S5. Several clinical 
trials have been published from the work in Finland, importantly 
using the gold standard autograft as comparison, which is needed 
to convince surgeons. A mixture of granules with autologous 
bone allowed the implantation of titanium implants in previously 
damaged jaw bone and showed more rapid bone repair compared 
to autograft alone (Turunen et al., 2004). Clinical trials for severe 
spondylolisthesis (displacement of vertebrae) used granules of 
1–2  mm. After 11  years, the fusion rate for the glass was 88% 
compared to 100% for autograft (Frantzen et al., 2011). Similar 
results were seen for treatment of osteomyelitis, where bone qual-
ity of the vertebrae is reduced due to bacterial infection (Lindfors 
et  al., 2010a). BonAlive was also compared to autograft in the 
same patients in spondylodesis procedures for treatment of spine 
burst fractures. At 10-year follow-up, five out of 10 implants had 
full fusion compared to all 10 autografts (Rantakokko et al., 2012).
In tibial fractures, in which surgery was required to restore 
joint alignment, BonAlive particles (0.83–3.15 mm) were placed 
inside the subchondral bone defects with metallic fixation (Pernaa 
et al., 2011). Full weight bearing was allowed when radiographs 
indicated healing had occurred, so the implants were loaded, 
and 11-year follow-up showed similar bone regeneration com-
pared to autograft. Some particles were still present at 11 years 
post operation (Heikkila et al., 2011). The lack of resorption of 
S53P4 may be due to glass composition, which has higher silica 
content than 45S5. Improvement over autograft was seen when 
BonAlive granules (1–4 mm) were used in post-tumor removal 
bone defects, with cortical bone thickness twice as thick as it was 
when autograft was used after 14 years (Lindfors et al., 2010b). 
Remodeling of the bone is slower than it was for autograft (e.g., 
after 12 months) (Lindfors et al., 2008).
A frontier that provided a scientific foundation for use of 
bioactive glass in bone regeneration was introduction of an 
appropriate in  vivo model that allowed the quantification and 
comparison of bone regeneration for different bioactive materials. 
Use of the same model, and the fact that the model is appropriate, 
will accelerate translation of new medical devices. Quantification 
and comparison of the effect of bioactive glass on regeneration of 
bone was based upon a series of important studies conducted by 
Oonishi et al. in Osaka, Japan (Oonishi et al., 1997, 1999, 2000). 
The Oonishi investigations used a critical size defect in a rabbit 
femoral condyle model to compare rates of bone formation in 
the presence of different types of bioceramic particles of the same 
particle size. The studies showed there are more bones formed 
in just 1 week in the presence of 45S5 bioactive glass particulate 
than are formed when synthetic HA or other calcium phosphate 
ceramic particulates are placed in the same type of defect for 
several weeks. After several weeks of bone regeneration, there was 
almost twice as much new bones present in the defect-containing 
bioactive glass. By 12 weeks, the amount of bone regenerated by 
Bioglass particles matched that originally present in the site. 
Wheeler et  al. demonstrated that the mechanical properties of 
the defect site were restored (Wheeler et  al., 2000). Bioactive 
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glasses and ceramics can, therefore, stimulate different rates of 
bone regeneration inside a bone defect, depending on the type of 
material (glass, ceramic, or glass–ceramic) and the composition 
and morphology of the device.
The next frontier was identifying what was really stimulating 
bone regeneration. While the in  vivo data showed differences 
between implants, they were not answering the question why there 
were differences. Initially, the dissolution of the 45S5 Bioglass 
particles were thought to cause more bone formation by the HCA 
layer forming more rapidly and by the glass degrading, making 
more space for bone ingrowth. This was not the complete story 
though. Dissolution is important, but mainly because the dis-
solution ions act as signals to the cells. This was revealed through 
in vitro experiments that showed critical concentrations of Si and 
Ca ions released from the glasses stimulated cells at the genetic 
level. Seven families of genes were upregulated when primary 
human osteoblasts are exposed to the ionic dissolution products of 
bioactive glasses (Xynos et al., 2000a,b, 2001). The gene expression 
occurs within 48 h, and includes enhanced expression of more 
than twofold of seven families of genes. The dissolution products 
can direct the cycle of a mixed population of cells. Cells that are 
not capable of differentiation into a mature osteoblast phenotype 
are switched into apoptosis by the ionic stimuli, eliminating them 
from the culture environment within the first days of exposure to 
the bioactive stimuli. Upregulated genes encode nuclear transcrip-
tion factors and cell cycle regulators (Xynos et al., 2001). Potent 
growth factors, especially insulin-like growth factor II (IGF-II), 
were increased by 3.2-fold along with IGF binding proteins and 
proteases that cleave IGF-II from their binding proteins.
Similar bioactive induction of the transcription of at least 
five ECM components (2- to 3.7-fold) and their secretion and 
self-organization into a mineralized matrix are responsible for 
the rapid formation and growth of bone nodules and differentia-
tion of the mature osteocyte phenotype. Shifts in osteoblast cell 
cycles were observed as early as 6 h for most experiments, with 
elimination (by apoptosis) of cells incapable of differentiation. 
The remaining cells exhibited enhanced synthesis and mitosis. 
The cells quickly committed to generation of ECM proteins and 
mineralization of the matrix (Xynos et al., 2000a,b, 2001).
Similar results were seen for fetal osteoblasts, where critical 
concentrations of Bioglass dissolution products stimulated differ-
entiation into mature phenotypes (Tsigkou et al., 2009). The roles 
of individual ions are partly understood: extracellular calcium 
ions increase IGF-II upregulation (Maeno et  al., 2005; Marie, 
2010) and glutamate production by osteoblasts (Valerio et  al., 
2009). Silica is released from Bioglass as silicic acid [Si(OH)4], 
which has been shown to stimulate collagen I production by 
osteoblasts (Reffitt et al., 2003). More detail on cellular response 
to individual ions is given in Hoppe et al. (2011).
eRA OF iNNOvATiON (2005–2025) 
FRONTieRS AND UNMeT CHALLeNGeS
There are many challenges still ahead for the clinical use of 
bioactive glasses that require advances in a fourth era, an era of 
innovation. Significant scientific and technological issues remain 
unanswered.
Frontier: Guidance of Stem Cells by 
Materials
Tissue regeneration through gene activation by controlled release 
of inorganic ions is a clinical reality that leads to enhanced 
osteogenesis. However, the role of the dissolution products on 
bone marrow-derived adult stem cells [mesenchymal stem cells 
(MSCs)] is more controversial, sometimes inducting osteogenic 
differentiation into osteoblast-like cells (Karpov et  al., 2008; 
Brauer et  al., 2010) and other times not (Reilly et  al., 2007). 
Human adipose stem cells differentiated into osteogenic cells 
when cultured with bioactive glasses in the presence of osteogenic 
supplements (Haimi et al., 2009; Ojansivu et al., 2015). However, 
neither adipose nor bone marrow MSCs differentiated in the 
presence of submicron bioactive glass spheres (Labbaf et al., 2011; 
Tsigkou et  al., 2014). The exact type and status of cell cycle of 
MSCs may be the reason for these differences.
An unmet challenge is to understand the fundamental 
mechanisms involved in ionic stimulation at the nucleus in the 
cell, of the many different cell types, that leads to upregulation 
or activation of genes. Another issue is that not all the articles 
explain exactly how the bioactive glass particles/dissolution 
products were applied or what supplements were used in the 
media. The fundamental mechanisms of stimulation of stem cell 
differentiation toward specific phenotypes must be understood to 
avoid potential tumorogenesis. A consolidation of data is needed 
for the frontier of stem cell guidance by bioactive glasses is still 
to be crossed.
Unmet Need: Bioactive Glass Scaffolds 
as Clinical Products
Particles and putties containing a variety of bioactive glass par-
ticulates are in widespread clinical use, but surgeons sometimes 
require large interconnected macroporous scaffolds for regenera-
tion of large bone defects. The porous architecture can guide bone 
regeneration, acting as temporary templates for tissue growth 
while allowing space for vascularization. At present, there are no 
large-scale porous bioactive glasses on the market. The reason is 
that it took until 2002 for the first porous bioactive glass scaffold 
with suitable pores to be developed (Sepulveda et al., 2002). This is 
because the original Bioglass 45S5 crystallizes as the particles are 
sintered together (Chen et al., 2006). Initially, this was overcome 
by avoiding sintering through the bottom-up sol–gel process, 
where gelation of nanoparticles in a sol (polycondensation) forms 
a glass network (Li et al., 1991). The room temperature gelation 
process allowed the introduction of a foaming step, with the aim 
of a surfactant, to produce interconnected pores with compres-
sion strength equivalent to porous bone (Jones et al., 2006). An 
X-ray microtomography image of a bioactive glass sol–gel foam 
scaffold is shown in Figure 3A.
More recently, melt-quenched glass scaffolds were produced 
through control of the sintering processing window by tailoring 
of the glass composition, which was achieved while maintaining 
bioactivity with new compositions, such as 13–93 (53 wt% SiO2, 
6 wt% Na2O, 12 wt% K2O, 5 wt% MgO, 20 wt% CaO, and 4 wt% 
P2O5) (Brink, 1997; Fu et  al., 2010) and ICIE16 (49.46  mol% 
SiO2, 1.07 mol% P2O5, 36.27 mol% CaO, 6.60 mol% Na2O, and 
6.60 mol% K2O) (Elgayar et al., 2005; Wu et al., 2011). An ICIE16 
FiGURe 4 | X-ray microtomography image of 3-D printed bioactive 
glass scaffolds. Modified with permission from Jones (2013).
FiGURe 3 | X-ray microtomography images of bioactive glass 
scaffolds (A) sol–gel foam and (B) melt-derived gel-cast foam. 
Modified with permission from Jones (2013).
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scaffold is shown in Figure  3B. Now sol–gel and melt-derived 
scaffolds exist but none are being put forward for use by medi-
cal device companies, even though comparative in vivo studies 
show benefit over current commercial porous bioactive ceramics 
(Minaberry and Jobbagy, 2011). This is because the improve-
ments in performance do not warrant the significant investment 
required to obtain FDA approval and upscale the manufacturing 
routes to commercial scale, as discussed above.
Frontier: Tissue engineered Constructs for 
Clinical Bone Regeneration
Tissue engineered constructs for replacement of large bone 
defects have been investigated for many years but are still not 
available as routine clinical products. Is it possible to achieve a 
stable vasculature in  situ in tissue engineering constructs that 
can be maintained in culture before implantation or be generated 
in vivo following implantation? Tsigkou et al. demonstrated that 
it is possible in mice models (Tsigkou et al., 2010), but can it be 
translated to the clinic? Does the scaffold affect in vitro vascu-
larization? Is the vascularization affected by mechanical load 
and changes of load with time? Numerous studies demonstrate 
bioactive stimulation of angiogenesis in  vitro; however, many 
studies are on one cell type, often fibroblasts. Most of the studies 
look for expression of VEGF from the cells, e.g., from fibroblasts 
(Day et al., 2004; Day, 2005), which was dependent on the dose of 
Bioglass dissolution ions (Keshaw et al., 2005). Mitogenic stimu-
lation of endothelial cells also occurred when they were cultured 
in the presence of Bioglass dissolution ions (Leach et al., 2006). 
Collagen/Bioglass 45S5 composites in rat calvaria also stimulated 
more neovascularization in 2  weeks than collagen alone (Leu 
et al., 2009), although similar results are not always seen in other 
studies. Extracellular calcium ions could be responsible for this 
effect (Aguirre et al., 2010). In vitro enhancement of angiogenesis 
has also been achieved by incorporating active ions, such as 
cobalt ions, in the glass network, which can trick the body into 
recognizing the implant site as hypoxic (low oxygen pressure). 
This triggers a cascade of processes to produce new blood vessels 
(Peters et al., 2005; Semenza, 2007; Azevedo et al., 2010, 2015). A 
question that needs answering is how long should there be pres-
ence of cobalt and a simulation of hypoxia in a bone defect for 
ideal bone regeneration? Medical device companies will also have 
to consider whether the benefits of cobalt ion release is worth the 
investment to claim the “drug-like” effects.
Frontier: Regenerative Scaffolds That Are 
Truly Load Bearing
Load-bearing devices that can be used in orthopedics over 
the long term that can also regenerate living bone are still not 
available clinically. This would be a frontier crossed that would 
certainly warrant the investment of medical device companies. 
Is it feasible to produce and test bioactive implants that have 
predictable 20-year lifetime survivability under simulated load-
bearing physiological conditions?
3-D printing has delivered bioactive glass scaffolds with inter-
connected pores similar in diameter to the porous foam scaffolds 
developed previously (Figure 4), but with compressive strengths 
at least an order of magnitude higher, increasing from 2.4 MPa for 
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the foams of 80% porosity (Jones et al., 2006) to >140 MPa for 
the 3-D printed scaffolds (Fu et al., 2011b). The reason for this is 
that the layer by layer printing process can deposit thick aligned 
struts (>50 μm), leaving wide channels in excess of 500 μm, with 
percentage porosities of 60% (Doiphode et al., 2011; Huang et al., 
2011; Kolan et al., 2011).
However, bioactive glass scaffolds are still brittle and therefore 
not suitable for all grafting applications, such as sites that are 
under cyclic loads. Tougher scaffolds are required that still have 
all the bioactive properties of Bioglass. One solution is to use 
composite materials (Rezwan et al., 2006); however, conventional 
composites of bioactive glass particles can be masked by the poly-
mer matrix and it is difficult to match degradation rates between 
the polymer and the bioactive glass. An alternative is inorganic/
organic hybrids made by the sol–gel process (Sanchez and In, 
1992; Novak, 1993; Jones, 2013). As the gelation process occurs 
at room temperature, polymers can be incorporated into the sol 
so that the polymer chains are dispersed between the assembling 
nanoparticles prior to gelation. This provides molecular scale 
interactions between the components (Figure 5A), which gives 
the unique potential for control of mechanical properties and 
degradation rate while providing a homogeneous surface (at the 
micron scale) for cell attachment (Arcos and Vallet-Regi, 2010; 
Jones, 2013). In order for congruent degradation to occur, some 
covalent bonds are needed between the organic and inorganic 
components (Figure 5A). Examples are silica/natural polymers: 
e.g., silica/gelatin (Ren et al., 2002; Mahony et al., 2010, 2014), 
silica/poly(gamma-glutamic acid) (Poologasundarampillai et al., 
2010, 2012, 2014; Valliant et al., 2013), silica/chitosan (Shirosaki 
et al., 2005, 2010; Connell et al., 2014), silica/polyester (Rhee et al., 
2002, 2004; Pandis et al., 2015), and silica/PEG (Liu et al., 2012; 
Russo et al., 2013; Catauro et al., 2015; Li et al., 2015). The foam-
ing method (Figure 5B) can be introduced to the sol–gel hybrid 
process (Mahony et al., 2010, 2014) or the sol to gel transition 
can be used to 3-D print the hybrids (Gao et al., 2013). One of 
the biggest challenges here is to be able to introduce calcium 
into the silicate network at these low processing temperatures. 
In sol–gel glass synthesis, using calcium salts, temperatures of 
450°C must be surpassed to allow calcium to enter the silicate 
network, which is too high for organic components. Therefore, 
alternative methods for calcium incorporation are needed to 
impart bioactivity (Valliant et al., 2013; Poologasundarampillai 
et al., 2014).
The frontier that must be crossed is of tuning the mechanical 
properties and degradation rates of these exciting new materials 
so that load can be shared with the host tissue and osteogenic 
cells experience a transfer of load, and mechanical transduction, 
so that high quality bone regenerates as the scaffold is remodeled 
by the host tissue.
Frontier: Use of inorganic Materials 
Deliver ions for Therapeutic Non-Bone 
Applications
Numerous soft tissue engineering applications have been inves-
tigated at an exploratory level but still require development into 
clinical products (Miguez-Pacheco et  al., 2015). Is it possible 
to obtain regulatory approval for clinical trials of soft tissue 
applications based upon limited in vitro and in vivo data and lack 
of understanding of basic biological mechanisms of soft tissue 
response to bioactive materials?
CONCLUSiON
Important frontiers have been crossed where synthetic materi-
als can bond with host bone, preventing fibrous encapsulation 
and creating a stable implant. Osteogenic cells are stimulated 
by inorganic bioactive glasses and their dissolution products. 
Frontiers still to be crossed in orthopedics are advanced bioactive 
biomaterials that can share load with host bone, transmit the load 
to the cells, and then degrade as the bone repairs. The concept of 
controlled delivery of active cations from a bioactive glass works 
for bone (osteostimulation). Other cations have been shown to 
stimulate other cells in vitro. A frontier to cross is the availability 
of bespoke bioactive devices for soft tissue therapy. Frontiers are 
only truly crossed when patients receive the benefits.
FiGURe 5 | Sol–gel hybrids: (A) schematic of the concept of inorganic/organic hybrids with bonding between components and (B) X-ray 
microtomography image of sol–gel foam hybrid scaffolds. Modified with permission from Jones (2013).
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